The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL
Open accessAbstract
Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor-intrinsic and -extrinsic determinants of response, we studied 44 adults with relapsed or refractory B-ALL (including 2 minimal residual disease positive) treated with blinatumomab using bulk tumor and single-cell sequencing. The overall response rate in patients with hematological disease was 55%, with a high response rate in those with CRLF2-rearranged Philadelphia chromosome–like ALL (12 [75%] of 16). Pretreatment samples of responders exhibited a tumor-intrinsic transcriptomic signature of heightened immune response. Multiple mechanisms resulted in loss of CD19 expression, including CD19 mutations, CD19-mutant allele-specific expression, low CD19 RNA expression, and mutations in CD19 signaling complex member CD81. Patients with low hypodiploid ALL were prone to CD19− relapse resulting from aneuploidy-mediated loss of the nonmutated CD19 allele. Increased expression of a CD19 isoform with intraexonic splicing of exon 2, CD19 ex2part, at baseline or during therapy was associated with treatment failure. These analyses demonstrate both tumor-intrinsic and -extrinsic factors influence blinatumomab response. We show that CD19 mutations are commonly detected in CD19− relapse during blinatumomab treatment. Identification of the CD19 ex2part splice variant represents a new biomarker predictive of blinatumomab therapy failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Self-citation
Cited by
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Philipp, N., Kazerani, M., Nicholls, A., Vick, B., Wulf, J., Straub, T., Scheurer, M., Muth, A., Hänel, G., Nixdorf, D., et al. (2022) · Blood · doi:10.1182/blood.2022015956 · Cited by 280
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL
Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2024) · Blood · doi:10.1182/blood.2024023930 · Cited by 41
Self-citation
Metadata
- Authors
- Zhao, Y., Aldoss, I., Qu, C., Crawford, J. C., Gu, Z., Allen, E. K., Zamora, A. E., Alexander, T. B., Wang, J., Goto, H., Imamura, T., Akahane, K., Marcucci, G., Stein, A. S., Bhatia, R., Thomas, P. G., Forman, S. J., Mullighan, C. G., & Roberts, K. G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-01-28
- Volume
- 137
- Issue
- 4
- Pages
- 471-484
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3083588228
- Cited by
- 164
- References
- 3
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. https://app.cochat.ai/papers/10.1182/blood.2020006287
- The paper
- Zhao, Y., Aldoss, I., Qu, C., Crawford, J. C., Gu, Z., Allen, E. K., Zamora, A. E., Alexander, T. B., Wang, J., Goto, H., Imamura, T., Akahane, K., Marcucci, G., Stein, A. S., Bhatia, R., Thomas, P. G., Forman, S. J., Mullighan, C. G., & Roberts, K. G. (2021). Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. https://doi.org/10.1182/blood.2020006287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.